[Skip to Content]
[Skip to Content Landing]
Article
March 1992

Suppression of Corneal Neovascularization With Cyclosporine

Author Affiliations

From the Cornea Service, Department of Ophthalmology, Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill (Drs Lipman and Epstein), and the Ocular Immunology Laboratory, Department of Ophthalmology, University of Illinois at Chicago (Drs Epstein and Hendricks).

Arch Ophthalmol. 1992;110(3):405-407. doi:10.1001/archopht.1992.01080150103037
Abstract

• We sought to determine if cyclosporine, which has been shown to suppress corneal allograft rejection, could also suppress corneal neovascularization induced by interleukin 2. Thirty A/J mice were treated with daily intramuscular injections of cyclosporine (25 mg/kg in olive oil) for 3 days before and 2 weeks following the intrastromal injection of 0.5 μL (5 IU) of recombinant mouse interleukin 2. Controls received intramuscular injections of olive oil. The mean area of corneal neovascularization 4, 8, and 12 weeks after injection was 9.2, 9.1, and 9.2 mm2, respectively, in controls, and 5.0, 5.2, and 5.2 mm2 in cyclosporinetreated mice (P<.02; Student's t test). Cyclosporine causes a significant reduction in interleukin 2-induced corneal neovascularization that may, in part, account for its ability to prolong corneal allograft survival in high-risk cases.

References
1.
Klintworth GK, Burger PC.  Neovascularization of the cornea: current concepts of its pathogenesis . Int Ophthalmol Clin . 1983;23:27-39.Article
2.
Stulting RD, Rindle JC, Nahmias AJ.  Patterns of herpes simplex keratitis in inbred mice . Invest Ophthalmol Vis Sci . 1985;26:1360-1367.
3.
Khodadoust AA.  The allograft reaction: the leading cause of late failure in clinical corneal grafts . In: Jones BR, ed. Corneal Graft Failure: Ciba Foundation Symposium 15 . Amsterdam, the Netherlands: Elsevier Science Publishers; 1973: 151-168.
4.
Lutty GA, Liu SH, Pendergrast RA.  Angiogenic lymphokines of activated T-cell origin . Invest Ophthalmol Vis Sci . 1983;24:1595-1601.
5.
Epstein RJ, Stulting RD.  Genetic control of corneal neovascularization (CNV) in inbred mice is dominantly inherited and non-H-2 . Invest Ophthalmol Vis Sci . 1986;27( (suppl) ):46.
6.
Watt SL, Auerbach R.  A mitogenic factor for endothelial cells obtained from mouse secondary mixed leukocyte cultures . J Immunol . 1986;136:197-202.
7.
Epstein RJ, Stulting RD.  Lymphocyte-induced corneal neovascularization in inbred mice . Invest Ophthalmol Vis Sci . 1987;28:1505-1513.
8.
Shepherd WFI, Coster DJ, Chin Fook T, Rice NSC, Jones BR.  Effect of cyclosporine-A on the survival of corneal grafts in rabbits . Br J Ophthalmol . 1980;64:148-153.Article
9.
Hill JC.  The use of cyclosporine in high-risk keratoplasty . Am J Ophthalmol . 1989;107:506-510.
10.
Newton C, Gebhardt BM, Kaufman HE.  Topically-applied cyclosporine in azone prolongs corneal allograft survival . Invest Ophthalmol Vis Sci . 1988;29:208-215.
11.
Belin MW, Bouchard CS, Frantz S, Chmielinska J.  Topical cyclosporine in high-risk corneal transplants . Ophthalmology . 1989;96:1144-1150.Article
12.
Mannis MJ, May WN.  Suppression of the corneal allograft reaction: an experimental comparison of cyclosporine-A and topical steroid . Cornea . 1983;2:95-101.Article
13.
Nussenblatt RB, Palestine AG.  Cyclosporine: immunology, pharmacology, and therapeutic uses . Surv Ophthalmol . 1986;31:159-169.Article
14.
Epstein RJ, Stulting RD, Hendricks RL.  Interleukin-2 induces corneal neovascularization in A/J mice . Cornea . 1990;9:318-323.Article
15.
Hendricks RL, Epstein RJ, Viana MAG, Hoffmann DA.  A reproducible method for injecting the mouse corneal stroma . Invest Ophthalmol Vis Sci . 1991;32:366-370.
16.
Hendricks RL, Epstein RJ, Tumpey T.  The effect of cellular immune tolerance to HSV-1 antigens on the immunopathology of HSV-1 keratitis . Invest Ophthalmol Vis Sci . 1989;30:105-115.
17.
Larsson EL.  Cyclosporine-A and dexamethasone suppress T-cell responses by selectively acting at distinct sites of the triggering process . J Immunol . 1980;124:2828-2833.
18.
Chabannes D, LeMautt B, Hallet MM, Tacgres Y, Soulilou JP.  Effect of cyclosporine on interleukin-2 receptor expression in a human alloreactive T-cell clone . Transplantation . 1988;46:975-1005.Article
19.
Waldman TA.  The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation . Environ Health Perspect . 1987;75:11-15.Article
20.
Bunjes D, Hardt C, Rollinghoff M.  Cyclosporine-A mediates immunosuppression of primary cytotoxic T-cell response by impairing release of interleukin-1 and interleukin-2 . Eur J Immunol . 1981;11:657-661.Article
21.
Kaufman Y, Chang AE, Robb RJ.  Mechanism of action of cyclosporine-A: inhibition of lymphokine secretion studied with antigen-stimulated T-cell hybridomas . J Immunol . 1984;133:3107-3111.
22.
Granelli-Piperna A, Keane M, Steinman RM.  Evidence that cyclosporine inhibits cell-mediated immunity primarily at the level of the T-lymphocyte rather than the accessory cell . Transplantation . 1988;46:975-1005.
23.
Kaswan RL, Salesburg MA, Ward D.  Spontaneous canine keratoconjunctivitis sicca: a useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops . Arch Ophthalmol . 1989;107:1210-1216.Article
24.
Gregory CR, Hietala SK, Pederen NC, Gregory TA, Floyd-Hawkins KA, Patz JD.  Cyclosporine pharmacokinetics in cats following topical ocular administration . Transplantation . 1989;47:516-519.Article
25.
Belin MW, Cavanagh HD, Chandler JW, et al.  Topical cyclosporine 2% ointment in the prevention of graft rejection in high-risk keratoplasty . Ophthalmology . 1990;97( (suppl) ):158.
×